Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F17%3AN0000150" target="_blank" >RIV/00064190:_____/17:N0000150 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S2213-2600(17)30219-9" target="_blank" >http://dx.doi.org/10.1016/S2213-2600(17)30219-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S2213-2600(17)30219-9" target="_blank" >10.1016/S2213-2600(17)30219-9</a>

Result language
angličtina
Original language name
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Original language description
Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)